San Diego, CA 6/26/2009 12:03:59 AM
JAZZ Pharma Jumps Over 50% in Price Gain on Phase III Trial Progress
Fibromyalgia treatment shows great promise so far.
Jazz Pharmaceuticals, Inc. (JAZZ) shares are rallying sharply today on good news regarding a potential fibromyalgia treatment. The company is expected to request the FDA approve JZP-6 as a treatment option for the pain disorder.
JZP-6 performed well as a fibromyalgia treatment during the company's Phase III testing of it in that capacity. The key ingredient in JZP-6 is the same active ingredient in Xyrem, which has already been approved as a sleep disorder treatment. Analysts expect the company's request to the FDA be made by the end of this year.
JAZZ is a specialty pharmaceutical company that develops and commercializes products for neurology and psychiatry primarily in the United States.
